BioSpace News Archive

Tevogen Bio, a clinical stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced that its Board of Directors has appointed Susan Podlogar to its Corporate Advisory Board.

Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes.

In the last few years, there’s been an increasing demand for economical and disposable medical device packaging solutions in the majority of countries, which has acted as the major factor driving the growth of the global medical device packaging market.

Near infrared imaging emerged as an effective diagnostic tool for not only medical applications but also discovering unknown images.

In the last few years, use of advanced medical devices over their conventional counterparts has highly increased, and surge in healthcare expenditure has played a pivotal role in the same.

The announcement of a recent investment from Semler Scientific in SYNAPS Dx, a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease, further positions DISCERN™ as a diagnostic for early AD.

OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber® products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1.

Avenge Bio, Inc., (“Avenge” or the “Company”) a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Science Advances describing the foundational, preclinical research establishing the LOCOcyte™.

The National Kidney Foundation hosts its 9th Annual Kidney Patient Summit bringing together more than 220 Voices for Kidney Health advocates in partnership with kidney organizations across the United States to virtually meet with their Congressional delegations and share their personal kidney journeys to help inspire action on behalf of the 37 million Americans who have kidney disease, also known as chronic kidney disease.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 PM ET.